Cargando…

APC and TP53 Mutations Predict Cetuximab Sensitivity across Consensus Molecular Subtypes

SIMPLE SUMMARY: Colorectal cancer (CRC) is a major cause of cancer deaths. Cetuximab is an FDA-approved, underutilized therapeutic targeting the epidermal growth factor receptor (EGFR) in metastatic CRC. To date, despite selection of patients with wild-type RAS, it is still difficult to identify pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thota, Ramya, Yang, Mingli, Pflieger, Lance, Schell, Michael J., Rajan, Malini, Davis, Thomas B., Wang, Heiman, Presson, Angela, Pledger, Warren Jack, Yeatman, Timothy J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582550/ https://www.ncbi.nlm.nih.gov/pubmed/34771559 http://dx.doi.org/10.3390/cancers13215394

Ejemplares similares

Ras Pathway Activation and MEKi Resistance Scores Predict the Efficiency of MEKi and SRCi Combination to Induce Apoptosis in Colorectal Cancer
por: Davis, Thomas Benjamin, et al.
Publicado: (2022)

An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy
por: Yang, Mingli, et al.
Publicado: (2022)

PTPRS Regulates Colorectal Cancer RAS Pathway Activity by Inactivating Erk and Preventing Its Nuclear Translocation
por: Davis, Thomas B., et al.
Publicado: (2018)

PTPRS drives adaptive resistance to MEK/ERK inhibitors through SRC
por: Davis, Thomas B., et al.
Publicado: (2019)

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53 mutations among molecular subtypes of HER2-positive tumors
por: Helland, Å, et al.
Publicado: (2005)

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
por: Sun, Hao, et al.
Publicado: (2020)

Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism
por: Clarke, Stephen L., et al.
Publicado: (2019)

Molecular profiling identifies distinct subtypes across TP53 mutant tumors
por: Chen, Xin, et al.
Publicado: (2022)

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC
por: Schell, Michael J., et al.
Publicado: (2016)

UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants
por: Hanson, Helen, et al.
Publicado: (2021)

Genomic landscape of pathogenic mutation of APC, KRAS, TP53, PIK3CA, and MLH1 in Indonesian colorectal cancer
por: Marbun, Vania Myralda Giamour, et al.
Publicado: (2022)

TP53 Mutation, Epithelial-Mesenchymal Transition, and Stemlike Features in Breast Cancer Subtypes
por: Coradini, Danila, et al.
Publicado: (2012)

TP53 somatic mutations in Asian breast cancer are associated with subtype-specific effects
por: Ragu, Mohana Eswari, et al.
Publicado: (2023)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

Association of β-Catenin, APC, SMAD3/4, Tp53, and Cyclin D1 Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Yan, Hongfeng, et al.
Publicado: (2022)

Systematic Review and Meta-analysis of TP53, HER2/ERBB2, KRAS, APC, and PIK3CA Genes Expression Pattern in Gastric Cancer
por: Ghojazadeh, Morteza, et al.
Publicado: (2022)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

The Role of TP53 in Adaptation and Evolution
por: Voskarides, Konstantinos, et al.
Publicado: (2023)

Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer
por: Kyndi, M, et al.
Publicado: (2005)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Comprehensive Identification of Deleterious TP53 Missense VUS Variants Based on Their Impact on TP53 Structural Stability
por: Tam, Benjamin, et al.
Publicado: (2021)

TP53 inhibitor PFTα increases the sensitivity of arsenic trioxide in TP53 wildtype tumor cells
por: Wang, Haiwei, et al.
Publicado: (2022)

Specific subtype distribution with impact on prognosis of TP53 single-hit and double-hit events in AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

A nomogram prediction model for the TP53mut subtype in endometrial cancer based on preoperative noninvasive parameters
por: Wang, Wei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vek284ia82lj3uu3t9tddfbeal